Voyager Acquisition Aktie - VACH

Voyager Acquisition Corporation (VACH) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

16,00

( -7,51% )

Gebot

8,30

Fragen

16,77

Volumen

1.026

0,00 Tagesbereich 0,00

8,40 52-Wochen-Bereich 18,16

Marktkapitalisierung

102,523M

Handelsende

17,30

Handelsbeginn

Letzte Trade

16.46

Letzter Handelszeitpunkt

13:47:09

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

US$ 17.909

Ausgegebene Aktien

6.407.685

Dividendenrendite (LTM)

Kurs-Gewinn-Verhältnis

47,67

Gewinn pro Aktie (EPS)

0,22

Erlöse (LTM)

Nettogewinn (LTM)

6,74M

Voyager Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the healthcare or healthc... Voyager Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the healthcare or healthcare related sectors. Voyager Acquisition Corp. was incorporated in 2023 and is based in Brooklyn, New York. Mehr anzeigen

Sektor

Branche

Website

www.voyageracq.com

Hauptsitz

Brooklyn, United States

Gegründet

2026

Voyager Acquisition Corporation is listed in the sector of the NASDAQ with ticker VACH. The last closing price for Voyager Acquisition was US$17,30. Over the last year, Voyager Acquisition shares have traded in a share price range of US$ 8,40 to US$ 18,16.

Voyager Acquisition currently has 6.407.685 shares in issue. The market capitalisation of Voyager Acquisition is US$102,52 million. Voyager Acquisition has a price to earnings ratio (PE ratio) of 47.67.

Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG

BROOKLYN, N.Y., March 13, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the...

Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG

BROOKLYN, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the...

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

ZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies...

VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform

ZURICH, May 29, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed...

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

ZURICH, May 20, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel...

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

ZURICH, SWITZERLAND, May 05, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and...

VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug...

Voyager Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 30, 2024

BROOKLYN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) announced that holders of the units...

Voyager Acquisition Corp. Announces Closing of $253,000,000 Initial Public Offering

BROOKLYN, N.Y., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) today announced that it closed its...

Voyager Acquisition Corp. Announces Pricing of $220,000,000 Initial Public Offering

BROOKLYN, N.Y., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) announced today the pricing of its...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	5.41	51.0859301228	10.59	18.16	9.45	19763	14.67796148	CS
4	5.35	50.234741784	10.65	18.16	9	10783	12.45971968	CS
12	4.32	36.9863013699	11.68	18.16	8.4	15004	12.11319426	CS
26	5.45	51.6587677725	10.55	18.16	8.4	83682	10.79704732	CS
52	5.67	54.8886737657	10.33	18.16	8.4	53803	10.70653987	CS
156	6.04	60.6425702811	9.96	18.16	8.4	70093	10.36586695	CS
260	6.04	60.6425702811	9.96	18.16	8.4	70093	10.36586695	CS

VACH - Frequently Asked Questions (FAQ)

What is the current Voyager Acquisition Corporation share price?

The current share price of Voyager Acquisition Corporation is US$ 16,00

How many Voyager Acquisition Corporation shares are in issue?

Voyager Acquisition Corporation has 6.407.685 shares in issue

What is the market cap of Voyager Acquisition Corporation?

The market capitalisation of Voyager Acquisition Corporation is USD 102,52M

What is the 1 year trading range for Voyager Acquisition Corporation share price?

Voyager Acquisition Corporation has traded in the range of US$ 8,40 to US$ 18,16 during the past year

What is the PE ratio of Voyager Acquisition Corporation?

The price to earnings ratio of Voyager Acquisition Corporation is 47,67

What is the registered address of Voyager Acquisition Corporation?

The registered address for Voyager Acquisition Corporation is 131 Concord Street, Brooklyn, New York, 11201

What is the Voyager Acquisition Corporation website address?

The website address for Voyager Acquisition Corporation is www.voyageracq.com

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Voyager Acquisition Corporation (VACH)

Voyager Acquisition Corporation (VACH) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Voyager Acquisition Corporation

VACH Neueste Nachrichten

Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG

Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

Voyager Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 30, 2024

Voyager Acquisition Corp. Announces Closing of $253,000,000 Initial Public Offering

Voyager Acquisition Corp. Announces Pricing of $220,000,000 Initial Public Offering

Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG

Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

VACH - Frequently Asked Questions (FAQ)

VACH Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Voyager Acquisition Corporation (VACH)

Voyager Acquisition Corporation (VACH) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Voyager Acquisition Corporation

VACH Neueste Nachrichten

Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG

Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

Voyager Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 30, 2024

Voyager Acquisition Corp. Announces Closing of $253,000,000 Initial Public Offering

Voyager Acquisition Corp. Announces Pricing of $220,000,000 Initial Public Offering

Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG

Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

VACH - Frequently Asked Questions (FAQ)

VACH Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich GRATIS und erhalten Sie:

Werbung entfernen